Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual MeetingBusiness Wire • 03/14/23
Zymeworks Inc. (ZYME) to Report Q4 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 02/16/23
Zymeworks shares gain on promising data for cancer drug in development with Jazz PharmaceuticalsMarket Watch • 01/19/23
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal AdenocarcinomaPRNewsWire • 01/19/23
MDA Breakout Stocks Week 3 - January 2023: High-Frequency Gainers To Give You An EdgeSeeking Alpha • 01/15/23
How Much Upside is Left in Zymeworks Inc. (ZYME)? Wall Street Analysts Think 65.75%Zacks Investment Research • 01/09/23
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023Business Wire • 01/04/23
Zymeworks Inc. (ZYME) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 12/23/22
Zymeworks nabs $350M from Jazz Pharmaceuticals after release of clinical trial dataGeekWire • 12/21/22
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for ZanidatamabPRNewsWire • 12/21/22
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of ZanidatamabBusiness Wire • 12/19/22
Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers SymposiumBusiness Wire • 12/14/22